MYGN

Myriad Genetics Inc. 10-Q Summary: Quarter Ended September 30, 2006

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Myriad Genetics, Inc., a biotechnology company focused on molecular diagnostics and drug development. The reporting period covers the three months ended September 30, 2006. The company operates three segments: research, molecular diagnostics, and drug development. As of November 2, 2006, the company had approximately 39.8 million shares of common stock outstanding.

Key Financial Metrics

Margins: The molecular diagnostic gross profit margin was 74% for the quarter, compared to 73% in the prior year period. The filing text does not provide a clear value for overall company operating margin due to the net loss position.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 34% year-over-year, driven primarily by a 43% increase in molecular diagnostic revenue ($30.9M vs $21.5M). This growth is attributed to increased sales, marketing, and education efforts.
• Research Revenue Decline: Research revenue decreased 25% to $2.7 million, primarily due to the successful completion of a research collaboration in the prior year quarter.
• Expense Increases:
  • Research and development (R&D) expenses rose 43% to $26.4 million, driven by ongoing clinical trials and drug discovery programs.
  • Selling, general, and administrative (SG&A) expenses increased 29% to $14.1 million to support business growth.
  • Share-based compensation expense increased significantly to $1.4 million from $0.2 million due to the adoption of SFAS 123R.
• Interest Income: Interest income surged 221% to $2.6 million, resulting from higher cash balances following a November 2005 equity offering and increased interest rates.
• Liquidity: Total cash, cash equivalents, and marketable securities decreased by $15.6 million (7%) from the previous quarter due to operational expenditures, though the company maintains a strong liquidity position with over $212 million in liquid assets.

Guidance, Outlook, and Risks

Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and new product launches. The company believes its current capital resources are sufficient to fund operations for at least the next two years.

Clinical Pipeline:

• Flurizan (Alzheimer's): Two Phase 3 trials are underway (one in the US with 1,684 patients, one in Europe/Canada/US enrolling 800 patients).
• MPC-7869 (Prostate Cancer): Phase 2b trial ongoing.
• Azixa, MPC-2130, MPC-0920: Various Phase 1 trials ongoing for solid tumors, blood cancers, and thrombosis.
• MPI-49839 (AIDS): In late-stage preclinical development.

Risks and Contingencies:

• Success depends on the progress and results of clinical trials, particularly for Flurizan and MPC-7869.
• Regulatory approval risks and potential delays in clinical timelines.
• Need for future financing if capital requirements exceed current resources.
• Intellectual property protection and potential patent infringement claims.
• Competition in both molecular diagnostics and therapeutic development.

Unusual Items: The filing notes the adoption of SFAS 123R (Share-Based Payment), which significantly increased reported compensation expenses compared to the prior year. No material legal proceedings were reported.

Investor Verification Checklist

• Verify the enrollment status and interim results of the two Phase 3 Flurizan trials for Alzheimer's disease.
• Confirm the timeline and budget for the Phase 2b MPC-7869 prostate cancer trial.
• Monitor the sustainability of the 43% growth rate in molecular diagnostic revenue and the associated gross margins.
• Assess the company's cash burn rate relative to its $212 million liquid asset base to validate the "two-year runway" claim.
• Review the status of the $17.6 million in unrecognized share-based compensation costs and its impact on future earnings.
• Check for any updates on the strategic collaborations with Abbott Laboratories and the NIH.